Quick Answer
Immunocore Holdings plc reported Total Revenue of $400.02 million for fiscal year 2025.
Immunocore Holdings plc Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $400.02M | +29.0% |
| 2024 | $310.20M | +24.4% |
| 2023 | $249.43M | +43.1% |
| 2022 | $174.36M | +377.9% |
| 2021 | $36.48M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $103.69M | +29.2% | +5.8% |
| June 30, 2025 | $97.96M | +29.9% | +4.3% |
| March 31, 2025 | $93.88M | +33.2% | +17.0% |
| September 30, 2024 | $80.25M | +23.7% | +6.4% |
| June 30, 2024 | $75.40M | +26.2% | +6.9% |
| March 31, 2024 | $70.50M | +29.0% | +8.7% |
| September 30, 2023 | $64.85M | — | +8.5% |
| June 30, 2023 | $59.76M | — | +9.3% |
- Immunocore Holdings plc showed an increase of +29.0% in Total Revenue compared to the prior fiscal year.
- Over the 2021–2025 period, Immunocore Holdings plc’s total revenue has grown by 996.4% (from $36.48 million to $400.02 million).
- The most recent figure is from Immunocore Holdings plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: